0.68 - 0.75
0.33 - 0.86
18.36M / 4.66M (Avg.)
34.50 | 0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
0.28%
Revenue growth under 50% of 3606.HK's 24.94%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
8.80%
Gross profit growth under 50% of 3606.HK's 31.83%. Michael Burry would be concerned about a severe competitive disadvantage.
85.33%
EBIT growth above 1.5x 3606.HK's 51.46%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
85.33%
Operating income growth above 1.5x 3606.HK's 20.71%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
87.44%
Net income growth above 1.5x 3606.HK's 19.48%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
62.43%
EPS growth above 1.5x 3606.HK's 20.00%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
62.43%
Diluted EPS growth above 1.5x 3606.HK's 20.00%. David Dodd would see if there's a robust moat protecting these shareholder gains.
15.43%
Slight or no buybacks while 3606.HK is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
15.37%
Diluted share change of 15.37% while 3606.HK is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-698.01%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-308.72%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
11795.63%
10Y revenue/share CAGR above 1.5x 3606.HK's 282.10%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
-12.09%
Negative 5Y CAGR while 3606.HK stands at 31.04%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-5.77%
Negative 3Y CAGR while 3606.HK stands at 16.76%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-9561.15%
Negative 10Y OCF/share CAGR while 3606.HK stands at 346.69%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-664.88%
Negative 5Y OCF/share CAGR while 3606.HK is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-1361.38%
Negative 3Y OCF/share CAGR while 3606.HK stands at 26.43%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
233.13%
Below 50% of 3606.HK's 706.13%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
384.15%
5Y net income/share CAGR above 1.5x 3606.HK's 32.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-14.85%
Negative 3Y CAGR while 3606.HK is 67.49%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
No Data
No Data available this quarter, please select a different quarter.
149.37%
5Y equity/share CAGR 1.25-1.5x 3606.HK's 130.48%. Bruce Berkowitz confirms if reinvested profits or buybacks explain the superior buildup.
62.96%
3Y equity/share CAGR at 50-75% of 3606.HK's 91.42%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-100.00%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-18.74%
Firm’s AR is declining while 3606.HK shows 14.45%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
30.58%
Inventory growth well above 3606.HK's 0.73%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
-2.55%
Negative asset growth while 3606.HK invests at 3.94%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.59%
Under 50% of 3606.HK's 8.12%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-99.86%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-35.78%
Our R&D shrinks while 3606.HK invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-46.41%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.